Healthcare / Medical Instruments & SuppliesShanghai
$29.41
+0.38 (+1.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $11.5M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
28.8x
↑EV/EBITDA
21.3x
↑ROE
15.1%
↑Gross Margin
63.9%
↑Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+12.1%
FCF CAGR
—
FCF margin
-5.7%
FCF / Net income
-0.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $326.7M · net income $85.2M · FCF $-18.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $326.7M | $326.7M | $272.4M | $253.6M | $232.0M |
| Net Income | $85.2M | $85.2M | $51.9M | $47.3M | $43.2M |
| EBITDA | $108.6M | $108.6M | $65.6M | $57.8M | $54.6M |
| EPS | 1.05 | 1.05 | 0.64 | 0.58 | 0.53 |
| Gross Margin | 63.9% | 63.9% | 58.5% | 56.1% | 57.3% |
| Operating Margin | 23.1% | 23.1% | 17.8% | 12.8% | 14.7% |
| Net Margin | 26.1% | 26.1% | 19.1% | 18.7% | 18.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 3.54 | 3.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.8M | $-18.8M | $11.5M | $64.5M | $2.7M |
| Returns | |||||
| ROE | 15.1% | 15.1% | 8.9% | 8.3% | 8.5% |
| Valuation | |||||
| P/E | 28.83 | 28.83 | 26.84 | 36.90 | 38.43 |
| EV/EBITDA | 21.30 | 21.30 | 20.30 | 26.60 | 29.83 |
| P/B | 4.22 | 4.22 | 2.40 | 3.05 | 3.27 |
| Growth & Yield | |||||
| Revenue Growth | 20.0% | 20.0% | 7.4% | 9.3% | — |
| EPS Growth | 64.1% | 64.1% | 10.3% | 9.4% | — |
| Dividend Yield | 3.4% | 3.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
35.5%
EPS terminal req.
$2.61
Spread vs growth
28.6%
5Y implied EPS CAGR
24.6%
EPS terminal req.
$3.16
Spread vs growth
39.4%
10Y implied EPS CAGR
17.1%
EPS terminal req.
$5.09
Spread vs growth
47.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.6%
Start / end P/E
35.8x → 28.0x
EPS bridge
0.64 → 1.05
Residual
-14.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.